Sitemap - 2022 - PsyMed Ventures Newsletter
Perspectives from Christian Angermayer, investor and founder in psychedelics
Soltara: an ethical and profitable ayahuasca retreat
DMTweet (& vote for our SXSW panel)
Microdosing (Part 3): The path to FDA approval with Diamond Therapeutics and MindMed
Microdosing (Part 2): The placebo effect with Balázs Szigeti
Microdosing (Part 1): James Fadiman and the fundamentals of microdosing
DMTweet: psychedelic tweet recap
DMTweet: a psychedelic tweet recap
How the DEA and FDA will regulate psychedelic medicine
DMTweet: a psychedelic tweet recap
The state of psychedelics: Dr. Rachel Yehuda and Zach Haigney (live recording at Soho House)
DMTweet: a psychedelic tweet recap
Empowering the next wave of psychedelic therapists: Journey Clinical
DMTweet: a psychedelic tweet recap
Osmind and the future of electronic health records in psychedelic medicine
DMTweet: a psychedelic tweet recap
DMTweet: a psychedelic tweet recap
Palo Santo’s $35M fund investing in the future of psychedelic therapeutics
DMTweet: a psychedelic tweet recap
DMTweet: a psychedelic tweet recap
Designing psychedelic mindstates, with Mindstate Design Labs
DMTweet: a psychedelic tweet recap
DMTweet: a psychedelic tweet recap
PsyMed Ventures, our $25M fund to invest in psychedelic medicine & mental health tech